FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M
Curis can now go full speed ahead with its leukemia trial after the FDA had imposed a partial clinical hold on the biotech last year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
